The Next Generation Migraine Therapies (NGMT) initiative is a comprehensive program designed to provide a multi-faceted approach to migraine education offered at no cost to healthcare providers including neurologists, primary care physicians and advanced practice providers. Brought to you by the American Headache Society, the program covers topics around the diagnosis and treatment of migraine, and updates on the latest science around the disease. Through a mix of regional in-person workshops, NGMT is designed to engage participants through didactic and interactive case study workshops. Register at no cost to attend our Dallas event here.
- Diagnosis and treatment
- Acute and Preventative treatment options
- What works well and what are the unmet needs?
- Risks for migraine progression
- The latest science
- State of the art therapeutic options
- Multi format administration options
- CGRP receptors as a target for small molecules: GPANTs
- Immunology, antibodies, and monoclonal antibodies
- Neuromodulation update
- Answer questions such as
- How can peripherally acting drugs treat migraine?
- What do I need to know about monoclonal antibodies that treat migraine?
- How do I best identify appropriate patients for the appropriate therapeutic option?
- What do I need to know to identify appropriate patients for these emerging therapies?
Online registration is now open. To register at no cost, click here.
To view the program brochure including preliminary program agenda, please click here.
Who Should Attend
This program is designed for Neurologists, Family Practitioners, Internists, and other health professionals who would like more information on the proper diagnosis and treatment of chronic migraine patients.
- Recognize the lack of awareness of the basic science and therapeutic potential of CGRP mAbs in the prevention of migraine.
- Identify mAbs, particularly CGRP and its receptor, provide effective prophylaxis of migraine.
- Address the need for greater understanding of how to apply new information about migraine pathophysiology to specific patients and potential treatments.
- Review data on the effectiveness and safety of mAbs in the treatment of migraine and learn how results in key sub-populations can help them predict which patients are likely to respond to treatment with CGRP mAbs.
AHS is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. AHS takes responsibility for the content, quality, and scientific integrity of this CME activity. AHS designates AMA PRA Category 1 credit(s)™ for this medical education activity, Comprehensive Migraine Education Program, for a maximum of 4.0 AMA PRA Category 1 Credit(s)™ for the morning program, 3.50 AMA PRA Category 1 Credit(s)™ for Workshop 1 and 3.5 AMA PRA Category 1 Credit(s)™ for Workshop 2.
This Live activity, Next Generation Migraine Therapies, from 04/06/2019 – 06/08/2019, has been reviewed and is acceptable for up to 8.25 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.